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Abstract. – BACKGROUND: Investigate if the
tyrosinase mRNA expression may be predictive
of the outcome on ultra-thin, thin, and thick
melanoma patients.
AIM: In our study, we sought to correlate tyrosi-
nase mRNA expression to the outcome in a group
of 71 patients with thick, thin and ultra-thin
melanomas.
MATERIALS AND METHODS: 71 patients
with melanomas underwent a SLNB (sentinel
lymph node biopsy) at the “Sapienza” University
of Rome. Among these, 38 patients had thin
melanomas, while the other 33 patients had
thick melanomas. In every patient’s sample his-
tology, immunohistochemistry and reverse tran-
scriptase-polymerase chain reaction (RT-PCR)
was completed. We then correlated tyrosinase
mRNA expression to the statistical analysis of
the outcome of patients.
RESULTS: Positivity of histology was found in
one patient (1.4%), immunohistochemistry in
five patients (7%), and tyrosinase in 52/71
(73.2%). Thickness and tyrosinase positivity
were predictive for disease progression (p <
0.05). The median follow-up was 58.24 months.
There were recurrences and/or deaths in both
groups of patients.
CONCLUSIONS: Nodal metastasis in melanoma
is uncommon, especially in patients with thin
melanomas. In this study, histology and im-
munohistochemistry were found to be non pre-
dictive for the risk of nodal metastases, while
instead, tyrosinase m-RNA expression appeared
to play a role in highlighting those patients with
a risk of disease progression. Moreover, no dif-
ferences among the thin melanoma groups of
patients (0.30-0.75 mm and 0.76-1.00 mm) were
observed.
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Introduction
In the United States, the incidence of thin
melanoma is increasing more rapidly than the in-
cidence of all cutaneous melanoma, including
those with rare location1-4. The American Joint
Committee on Cancer (AJCC)5, in 2001, estab-
lished a staging system that classified tumours
with a thickness ≤ 1.00 mm, as a thin melanoma,
thus changing the threshold for a T1 melanoma
from 0.75 to 1 mm. Thin melanoma generally in-
dicates low-risk disease and good prognosis. Nev-
ertheless, the presence of ulceration (the Clark’s
level III-IV) have been recognised as (an adverse
histological characteristic that may lead to a differ-
ent prognosis)6. Since that time, the thin
melanoma subset of patients is currently under in-
vestigation in order to find any additional risk fac-
tor that may allow a sub staging of this group.
However, long-term follow-up studies have
shown thin melanomas to be associated with dis-
ease progression; 9.4% of these patients recur in a
median follow-up of 11 years, whereas the disease-
free survival at 20 years was reported at 59%7.
Nevertheless, the American Joint Committee on
Cancer (AJCC) data of survival at 10 years of fol-
low-up for patients with thin primary melanoma is
87.9% for stage IA, and 83.1% for stage IB8, and as
underlined by Halpern and Marghoob: “the qualita-
tive description of the progression of thin melanoma
has accordingly shifted from excellent to good”9.
Recently, intraoperative lymphatic mapping
and sentinel lymph node biopsy (SLNB), the first
sites of melanoma metastases10, were developed
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Tumour thickness and level of invasion were
documented, as was the tumour type and stage of
disease, according to TNM classification of the
International Union Against Cancer5. The Bres-
low thickness ranged between 0.3 mm and 9.00
mm (mean Breslow thickness 1.77 mm). The pa-
tients with stage IA of disease were 34/71
(47.8%), those with stage IB were15/71 (21.1%),
whereas the patients with stage of disease II A,
IIB and IIIA were 13/71 (18.3%), 3/71 (4.2%)
and 6/71 (8.45%), respectively. After surgical ex-
cision, SLNs were frozen in liquid nitrogen and
stored at –80°C, until used for the reaction of RT-
PCR. The presence of capsular nevus cells in
SLNs was tested by histologic examination, and
the positive samples were excluded from the
study. A total of 71 SLNs excised from an equal
number of patients were collected. In order to
verify, by the statistical analysis, the usefulness
of the tyrosinase RT-PCR assay in SLN of
melanoma patients, we divided our specimens in-
to three different groups of samples according to
the Breslow thickness. The first comprised 33
SLN, obtained from patients with a melanoma
thickness >1.00 mm; a second group of 26 SLN,
from patients with melanoma’s thickness includ-
ed between 0.76 mm and 1.00 mm, which we
identified as “normal Thin” (nThin); and the last
group of samples with 12 SLN from patients
with a melanoma with a Breslow thickness <0.76
mm, which we called “very thin” (vThin)
melanoma. The characteristics of patients and
samples are included in Table I.
Lymphatic Mapping and SLN Biopsies
Lymphatic mapping and SLN biopsies were
successfully performed at the “Sapienza” Univer-
sity of Rome, Department of Plastic and Recon-
structive Surgery, as previously described17. Each
SLN was examined by Hematoxylin-Eosin
(H&E), and Immunohistochemistry (IHC), and
RT-PCR molecular assay.
Histology and Immunohistochemistry
The sentinel nodes were analysed histological-
ly in serial sections of paraffin-embedded sam-
ples, using Haematoxylin and Eosin (H&E)
staining, and Immunohistochemistry (IHC), by
using antibodies against HMB-45 antigen and S-
100 protein (Dakopatts, Hamburg, Germany),
and detected with the avidin-biotin-peroxidase
technique. Negative controls were obtained if
normal animal serum was used instead of specif-
ic primary antibodies.
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and have been widely accepted as a precise tool
to classify early-stage-melanoma, and in most
cases, the sentinel node is the only lymph node
invaded by tumour cells11. The SLNB in these
patients may be useful for the detection of tu-
moral cells and for a good prognosis of patients.
The SLNB is routinely used for patients with le-
sions of >1.0 mm, however with selected pa-
tients, those with thin melanomas (≤1 mm),
SLNB has been introduced to study the progno-
sis of these patients. The indication for the use of
SLNB in patients with thin melanoma is not well
established, and some questions remain unre-
solved. The controversial benefit, the low per-
centage of positive SLN, the good prognosis for
most of them and the associated cost are dis-
cussed by scientists12.
To date, the Breslow’s tumour thickness is one
of the most powerful predictor factors of survival
in melanoma patients with stage I and II of the
disease5. To detect the presence of melanoma
cells in sentinel lymph nodes (SLNs) and in pe-
ripheral blood, the Reverse Transcriptase-Poly-
merase Chain Reaction (RT-PCR) assay was used
for the first time in 1991, as a sensitive method to
identify tyrosinase mRNA13-15. To date, many
groups of work have focused their studies on the
molecular profile of SLNs in melanoma patients,
by using techniques of molecular biology, such
as the RT-PCR assay, to obtain a better analysis
of the specimens, even if very few data concern-
ing the molecular pattern of SLN in thin
melanoma, are present16.
In our study, we sought to correlate tyrosinase
mRNA expression to the outcome in a group of
71 patients with thick, thin and very-thin
melanomas, by the statistical analysis, in a medi-
an follow-up period of 58.24 months.
Materials and Methods
Patients and Samples
Seventy-one patients (35 males and 36 fe-
males), between 17 to 81 years (mean age 54.5),
affected by malignant melanoma, were enrolled
in this study at the Department of Dermatology
and Plastic Surgery of the “Sapienza” University
of Rome. An informed consent was obtained
from all patients. Patients with primary tumours
of Breslow thickness <.75 mm were offered
SLNB, only if they had one of the following cri-
teria: Clark level III or IV, ulceration, regression
or patient demand.
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Follow-up Tumor
OS months DFS months OS Site Clark Breslow
135.2 24 # 3 2 0.3
36.3 36.3 d.f. 1 3 0.3
58 58 d.f. 1 3 0.35
44.9 44.9 d.f. 1 2 0.4
18 18 d.f. 1 3 0.5
36.9 36.9 d.f. 1 3 0.54
24 24 d.f. 1 2 0.55
41.3 41.3 d.f 1 3 0.6
82.56 82.56 d.f. 1 3 0.6
27 27 d.f. 2 4 0.6
91.19 91.19 d.f. 3 2 0.65
21 21 d.f. 2 3 0.65
24.56 24.56 d.f. 1 3 0.8
60 60 d.f. 1 3 0.84
49.1 49.1 d.f. 2 3 0.85
83.86 83.86 d.f. 3 3 0.85
48 38 #* 1 2 0.9
109 109 d.f. 1 3 0.9
77.53 77.53 d.f. 1 3 0.9
44 44 d.f. 1 3 0.93
27 27 d.f. 1 3 0.95
24.2 24.2 d.f. 2 4 0.98
83 83 d.f. 0 3 1
58.73 58.73 d.f. 1 3 1
20.56 20.56 d.f 1 3 1
84.06 84.06 d.f. 1 3 1
126 126 d.f. 2 3 1
64 64 d.f. 2 3 1
48.73 48.73 d.f. 1 3 1
48.96 48.96 d.f. 1 3 1
52.167 52.167 d.f. 2 3 1
77.96 77.96 d.f. 2 3 1
78.39 78.39 d.f. 2 3 1
70 70 d.f. 3 3 1
32.6 32.6 d.f. 1 4 1
55.06 55.06 d.f. 2 4 1
57.96 57.96 d.f. 3 4 1
12 12 d.f. 1 3 1
89.43 89.43 d.f. 1 3 1.11
88.26 88.26 d.f. 2 4 1.21
86.93 86.93 d.f. 3 3 1.3
83.8 83.8 d.f. 1 3 1.32
94 90 #* 1 3 1.4
17.667 9.6667 #* 2 4 1.5
102.13 102.13 d.f. 2 4 1.5
49.267 48.267 #* 3 3 1.5
43.167 34.4 #* 2 4 1.5





Total RNA extracted from the frozen tissues
was reverse transcribed and amplified with the ty-
rosinase upstream and downstream primers as pre-
viously described17. All the recommended precau-
tions were taken to avoid the possibility of false-
positive results. The preparation of the reaction
mixture and the analysis of amplified products
were carried out in separate rooms. Each RT-PCR
experiment included a sample without RNA as a
negative control. The analysis of the RT-PCR
products was performed by electrophoresis on 2%
agarose gel of 20 µl of the amplification products,
and only samples that showed the specific amplifi-
cation product, were considered positive.
Follow-up
Patients were examined prospectively for re-
current or metastatic disease at three-month inter-
vals. The evaluation consisted of a physical exam-
ination and routine blood investigations during a
median follow-up of 58.24 months; the minimum
follow-up time was 10.567 month and the maxi-
mum follow-up time was 135.2 months. An ultra-
sound examination of the regional lymph nodes
basins and the abdomen, and a chest X-ray, were
performed at least once a year. Computed Tomog-
raphy (CT) and Magnetic Resonance Imaging
(MRI) were also performed in patients with find-
ings suggestive of metastatic melanoma.
Statistical Analysis
To establish those variables that were statisti-
cally significant for death and/or progression of
the disease, all data were entered into a Microsoft
Excel spreadsheet and analysed as follows: con-
tingency tables were evaluated by the χ2 test. The
overall survival curves were compared by the
Kaplan-Meier method, with the log-rank test; a p
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Follow-up Tumor
OS months DFS months OS Site Clark Breslow
116.43 116.43 d.f. 2 2 1.7
87.63 87.63 d.f. 2 4 1.89
77.433 77.433 d.f. 2 4 2
14.8 7.8667 #* 1 3 2
36.067 25.333 #* 1 3 2
121.73 121.73 d.f. 1 3 2
93.1 93.1 d.f. 1 3 2.1
69.4 69.4 d.f. 2 4 2.25
21.067 1.5 #* 1 4 2.75
42.333 6.4667 #* 1 4 3
82.467 64.033 #* 1 4 3
11.333 8.1667 #* 1 4 3
10.567 5.8333 #* 2 4 3
45.333 44.833 #* 2 4 3
42.267 28.433 #* 2 4 3
19.167 17.9 #* 1 4 3.25
15.367 1.1 #* 1 4 3.4
41.9 24.1 #* 1 4 3.75
61.433 56.433 #* 2 4 4
65.533 65.533 d.f. 3 4 4.5
45.433 23.433 #* 1 5 5
124.06 24.067 # 2 4 6
11.8 11.333 #* 1 5 7
90.39 90.39 d.f. 0 5 9
Table I (Continued). Features of melanoma patients and results.
Abbreviations: P: patient; OS: Overall survival; DFS: disease free survival; d.f.: patients disease free; *Patient died; #Patient
with disease progression; Primary melanoma site: 0 = Head and neck, 1 = Trunk, 2 = Lower extremities, 3 = upper extremities;
Tyr, Tyrosinase; H&E, Hematoxylin-Eosin; IHC, Immunohistochemistry.
value of < 0.05 was considered statistically sig-
nificant. A statistical analysis was performed




A simultaneous analysis of histology and IHC
was performed on 71 SLNs of melanoma patients.
One patient was positive at the histologic ex-
amination (IHC assay as well). This patient died
due to disease. Another five SLNs obtained from
five patients showed a negative result by the his-
tologic examination, and a positive result at the
IHC assay. Four of these five patients are current-
ly disease free, and one patient had progression
of disease.
RT-PCR
In order to investigate the suitability of samples,
all RNAs were subjected to RT-PCR using glycer-
aldehyde-3-phosphate deydrogenase (GADPH)
specific primers. They were all found suitable for
PCR analysis. Tyrosinase expression was found
positive in 52/71 (73.23%) specimens, and nega-
tive in 19/71 (26.77%) of examined samples. Con-
cerning the RT-PCR-positive-group, 18/52
(34.5%) patients with a SLN positive for tyrosi-
nase showed progression of disease and died, 2/52
(4%) had progression of disease, and the remain-
ing 32/52 (61.5%) are currently disease free.
Among the 19 patients with SLN that showed neg-
ative for tyrosinase, 2/19 (10.5%) had progression
of disease and died because of disease, whereas
17/19 (89.5%) are still disease free.
In the stage I disease group of patients (49 of
71 SLNs) 32 SLNs were positive for tyrosinase
expression while 17 were negative; within the 32
positive patients 26/32 are, at moment, disease
free, one patient had progression of disease and
5/32 of patients had disease progression and then
died of melanoma. The follow-up of tyrosinase
negative patients in disease-stage I (16/17)
showed one progression and death due to the dis-
ease while 16 are disease free.
In the stage II disease group of patients (16 of
71 SLNs) 15 SLNs were positive for tyrosinase
expression and only one patient with a SLN neg-
ative for tyrosinase expression is, at moment, dis-
ease free; of the 15 RT-PCR assay positive pa-
tients, 3/15 are disease free and 12/15 had pro-
gression of disease and then died.
In this work only 6 SLNs were analysed from
patients with stage III of disease. One SLN was
negative for tyrosinase, and the patient was dis-
ease free at follow-up. The remaining 5 SLNs
were found to be positive for tyrosinase expres-
sion. 3 patients were disease free, 1 patient had
progression of disease and one died for
melanoma. In Figure 1 are summarized the re-
sults obtained from RT-PCR assay analyzed re-
spect to disease stage and to follow-up. Agarose
gel electrophoresis of RT-PCR products is shown
in Figure 2 (Panel a). The characteristics of pa-
tients, samples, outcome of patients and results
obtained from Histology, IHC and RT-PCR as-
say, are shown in Table II.
Statistical Analysis
The median follow-up in our series was 58.24
months (range 10.567-135.2).
Table II shows patient characteristics and, ac-
cording to the univariate analyses (χ2 test), the
risk of death or disease progression. The death
risk is related to Breslow’s thickness (p trend <
0.0001), Clark’s level (p trend = 0.0007) and age
(p = 0.0145 p trend = 0.0358), while sex, primary
melanoma site, drainage site, histotype and ty-
rosinase positivity showed no statistical signifi-
cance. The disease progression is correlated to
Breslow’s thickness (p trend < 0.0001), Clark’s
level (p trend = 0.0023), age (p = 0.0031 p trend
= 0.0106) and tyrosinase positivity (p = 0.0496)
while sex, primary melanoma site, drainage site
and histotype showed no statistical significance.
The Kaplan Meier survival curve (Figure 1
Panel b) showed that tyrosinase positivity was
statistically significant (p = 0.0485) as a prognos-
tic factor for melanoma patients.
Discussion
Recently, many studies have been published
concerning the prognostic value of SLN in thin
melanoma. In the first meta analysis focused on
SLNB in this subset of patients recently pub-
lished, has been underlined as, to date, the avail-
able data are not adequate to establish criteria for
patients selection and to draw conclusions re-
garding SLNB in thin melanoma patients19. Very
little literature is available on the molecular re-
search of thin melanoma, mainly performed by
techniques such as the histology, IHC20,21 and
rarely the RT-PCR assay15. The RT-PCR method
can detect one tumour cell out of 106 to 107 non-
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Figure 1. The figure shows the results obtained by RT-PCR essay from LNSs patients, divided by stage. Disease free patients
(DF), patients in progression (P), and patients died after progression (P+D).
Figure 2. A, Lanes 1-4 Samples from Sentinel Lymph-Nodes analyzed for the expression of GAPDH and Tyrosinase. Lane 5
Positive control (RNA from M14 cell line). Lane 6 Negative control (sample without RNA) bp (Base pair). B, Kaplan-Meyer
disease free survival rate. The probability of disease free survival is shown for patients with SLN positive for Tyrosinase ex-
pression and for patients with SLN negative for Tyrosinase expression.
A
B
tumour cells, thus identifying a population of pa-
tients at risk of recurrence, who are not identified
by routine assay. Nevertheless, to date the real
utility of the detection of tyrosinase mRNA by
RT-PCR assay is not well defined for the re-
search of occult melanoma cells both in SLN and
in circulating bloodstream22,23.
In the last few years, we focused our attention
on the research of a molecular markers profile in
SLN, which may be useful as prognostic factors
for melanoma patients17,24,25. In this study, we
sought to investigate the tyrosinase expression of
SLNs from 71 patient with a Breslow range from
0.3 mm to 9.0 mm, in order to verify if its ex-
pression could be a useful approach to predict the
outcome of patients in very-Thin, nThin, and
thick melanoma patients in a median follow-up
time of 58.24 months.
Even though the sentinel lymph node mapping
and dissection is now regularly performed for pri-
mary melanomas > 1 mm, this procedure is not
well accepted for thinner lesions, in consideration
of the low incidence of lymph node metastases; on-
ly few research centres have considered a lower cut
off point (> 0.75 mm) to perform the SLNB26-29.
The detection of a subset of patients with dis-
ease spread, allows for additional therapies such as
surgery, adjuvant systemic interferon therapy, ad-
juvant radiation therapy, or enrolment in adjuvant
experimental clinical trials for chemotherapy, au-
tologous vaccine30 or monoclonal antibodies31.
The advantage of highlighting a small sub-
group of node-positive patients has to be correlat-
ed to the potential unnecessary morbidity of the
surgical procedure and the increased costs of the
entire thin-group treated by SLNB.
Even though adjuvant trials have not suffi-
ciently detected survival differences by tumour
thickness, the adjuvant surgery seems to be more
effective in thinner lesions, presumable for a low-
er risk of distant metastatic disease, already be-
ing present at the time of surgery32. Unfortunate-
ly, due to the small number of patients with very-
thin lesions we could not statistically compare
the results obtained by SLNs excised from this
group of patients with the results obtained on
SLNs belonging to patients with thin and thick
melanomas.
Among the 38/71 patients enrolled with a le-
sion of Breslow ≤ 1.00 mm, two showed progres-
sion of disease, whereas the other 36 patients are
currently disease free. The first patient, a female
of 62 years, had a melanoma with a Breslow
thickness of 0.3 mm and the SLN analysed, re-
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χ2 test χ2 test
N° of endpoint: death endpoint: progression
Characteristic patients % p value p value
Tyrosinase
Positive 52 73.23 p = 0.0892 p = 0.0496
Negative 19 26.77
Sex
Male 35 49.29 p = 0.1634 p = 0.3956
Female 36 50.71
Age
≤ 40 13 18.32 p = 0.0145 p = 0.0031
41-60 27 38.02 p trend = 0.0358 p trend = 0.0106
> 60 31 43.66
Primary melanoma site
Head and neck 2 02.81 p = 0.4771 p = 0.7482
Trunk 38 53.52
Upper extremities 8 11.28
Lower extremities 23 32.39
Drainage site




≤ 0.75 12 16.90 p trend < 0.0001 p trend < 0.0001
0.76-1.00 26 36.61
1.01-4.00 28 39.43
> 4.00 5 07.06
Table II. Patients characteristic (n° 71).
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sulted as tyrosinase positive. This patient had a
recurrence of disease 24 months after diagnosis
and to date, with an overall survival of 135.2
months, is disease free. The second patient, a
male of 40 years, with a melanoma with a Bres-
low of 0.9 mm had recurrence of disease 38
months after the diagnosis, and died 10 months
later. The SLN excised from this patient resulted
negative for the expression of tyrosinase. The sta-
tistical analysis of all data showed as the tyrosi-
nase positive expression identify a subset of
melanoma patients at risk of disease progression
(p = 0.0496) by χ2 test; in addition, the Kaplan
Meier exact test highlights in the tyrosinase posi-
tive expression a negative prognostic factor with
a p = 0.0485 in SLNs from melanoma patients
with a Breslow range from 0.3 to 9 mm. 
These preliminary results may lead to some
considerations: (1) It should be auspicable, in our
opinion, to perform the SLNB on patients with
nThin and very-Thin melanoma, although some
literature studies suggest that these groups of pa-
tients were overtreated by undergoing SLNB32,34.
Our data are in agreement with long-term and
mid-term follow-up studies that show recur-
rences for thin melanoma patients35. (2) The re-
sults obtained by the Kaplan-Meier exact test in
an adequate median follow-up period (58.24
months) are encouraging. We believe that the de-
tection of tyrosinase expression in SLNs may add
additional prognostic information to other vali-
dated prognostic factors such as the Breslow’s
thickness and Clark level, even if its role in the
staging of melanoma patients must be further in-
vestigated; in addition, we believe that the tyrosi-
nase negative expression may identify a subset of
patients at lower risk of progression of disease.
We obtained 19 SLNs negative for tyrosinase ex-
pression belonging to patients at different stage
of disease and among these 18/19 (95%) are dis-
ease free and only one patients died due to the
disease. (3) The possibility of having disease pro-
gression in both groups of nThin and vThin
melanoma patients suggests that the disease has
already spread at the time of diagnosis, also for <
.75 mm melanoma. The extension of SLNB to
patients with a melanoma thickness < .75 mm
has to be valuated and the molecular profile of
SLNs further investigated, as well as the SLNs
from nThin and the thick melanoma patients. The
lower limit of the class of patients to be treated
with SLNB will probably be defined by statisti-
cal analysis on the results obtained by molecular
studies performed to elucidate the differences in
the molecular profile during the tumour progres-
sion on large numbers of patients with vThin and
nThin melanomas with more than 10 years of
follow-up.
For this reason the enrolment of thin melanoma
patients for SLNB has to be considered still inves-
tigational (the majority of our very-Thin patients
were volunteer demanding for the surgery) be-
cause no differences have been showed by the
analysis of this two subset of patients. The majori-
ty of our samples resulted negative at H&E and
IHC and the result obtained by the Kaplan Maier
test (borderline for statistical significativity) prob-
ably is of comparable to a typical group of patients
with melanoma > 1 mm. 
Conclusions
From the results obtained emerges as tyrosi-
nase positive expression is predictive of disease
progression and not for death; we can speculate
that as demonstrated by Orlow et al36 the pigmen-
tary change in melanoma progression require
variations in expression of pigment genes may
explain the high numbers of SLNs positive for
tyrosinase expression obtained by an assay much
more sensitive respect to H&E and IHC. Al-
though other work performed on a larger number
of sample are present in literature on the real util-
ity of SLNB for thin melanoma, we conclude
that this work, performed for the first time with
RT-PCR on very thin melanoma group of pa-
tients, could be one of the first report in con-
structing a large study on thin melanoma.
In future, more refinements in molecular stag-
ing for melanoma would provide additional in-
formation of prognostic value for the most part
for patients with vThin and nThin melanoma.
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